<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969354</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2021-KL092-02</org_study_id>
    <nct_id>NCT04969354</nct_id>
  </id_info>
  <brief_title>Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma</brief_title>
  <official_title>Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Hospital of Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting&#xD;
      CAIX in the treatment of advanced renal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a clinical study and divided the trial into two phases.&#xD;
&#xD;
      Phase 1 (climbing test) : 12 patients were randomly divided into 4 groups (n=3). 12 patients&#xD;
      were treated with cyclophosphamide at the dose of 60mg/kg/d 8-7 days before CAR-T cell&#xD;
      infusion, and fludalabine at the dose of 25mg/m^2/d 6-2 days before CAR-T cell infusion. 5 mg&#xD;
      anti-human CAIX monoclonal antibody (G250) was injected into the hepatic artery of each&#xD;
      patient by an interventional catheter on the day before CAR-T cells infusion. On Day 0, CAR T&#xD;
      cells were injected into patients in group 1, 2, 3 or 4 at the dose of 1x10^7/ person,&#xD;
      1*10^8/ person, 1*10^9/ person or 1*10^10/ person, respectively. The infusion time is about&#xD;
      15-30min. On day 0-14, IL-2 (75000IU/kg) was injected subcutaneously once a day. From day&#xD;
      15-28, IL-2 (75000IU/kg) was subcutaneously injected into the patients three times a week.&#xD;
      The purpose of this study is to assess subjects' MTD (maximum tolerated dose) against CAR T&#xD;
      cells.&#xD;
&#xD;
      Phase 2: After determining the appropriate therapeutic dose for patients with renal cell&#xD;
      carcinoma, 8 patients received the same pre-treatment of chemotherapy and G250 antibody.&#xD;
      Then, the appropriate therapeutic dose of CAR T cells according to the results of phase 1 was&#xD;
      infused on Day 0. On day 0-14,IL-2 (75000IU/kg) was given subcutaneously once a day. On day&#xD;
      15-28, IL-2 (75000IU/kg) was given subcutaneously three times a week.&#xD;
&#xD;
      Peripheral blood was collected every 4 weeks to evaluate proliferation and survival of CAR-T&#xD;
      cells. After 6 months of close follow-up, subjects will undergo a medical history evaluation,&#xD;
      physical examination, and blood tests quarterly for 2 years. After this assessment, subjects&#xD;
      will be enrolled in an annual telephone follow-up and questionnaire study for up to five&#xD;
      years to evaluate treatment for long-term health problems, such as recurrence of malignant&#xD;
      tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation:Incidence and severity of adverse events</measure>
    <time_frame>First 1 month after CAR-T cells infusion</time_frame>
    <description>To evaluate the incidence and severity of possible adverse events within one month after targeted CAIX CAR-T infusion, including cytokine release syndrome and on-target toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness evaluation</measure>
    <time_frame>3 months after CAR-T cells infusion</time_frame>
    <description>In order to observe the efficacy of CAR-T cells after infusion, total remission rate (ORR), complete remission (CR), partial remission (PR), disease stability (SD) or progression (PD) will be used for evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months after CAR-T cells infusion</time_frame>
    <description>Progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months after CAR-T cells infusion</time_frame>
    <description>Overall survival (OS) time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>CAR-T cell immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The registered patients will received CAR-T cell immunotherapy for the new specific chimeric antigen receptor of CAIX antigen by infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cell immunotherapy</intervention_name>
    <description>This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.</description>
    <arm_group_label>CAR-T cell immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged from 18 to 70 years old;&#xD;
&#xD;
          2. The patient's ECOG score is ≤ 2;&#xD;
&#xD;
          3. Patients with advanced or metastatic renal cell carcinoma:&#xD;
&#xD;
        (1) have received first-line and second-line targeted therapy in the past; (2) Previous&#xD;
        immunization with PD-1/L1 and ≤2 regimens; (3) Unable to tolerate targeted therapy or&#xD;
        immunotherapy. 4.There are measurable or evaluable lesions; 5.The main tissues and organs&#xD;
        of patients function well:&#xD;
&#xD;
          1. liver function: ALT/AST&lt; 3 times the upper limit of normal value (ULN);&#xD;
&#xD;
          2. Renal function: creatinine &lt; 220 μmol/L;&#xD;
&#xD;
          3. Lung function: indoor oxygen saturation ≥ 95%;&#xD;
&#xD;
          4. Cardiac function: Left ventricular ejection fraction (LVEF)≥40% 6.Patients or their&#xD;
             legal guardians voluntarily participate and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infectious diseases (such as HIV, active hepatitis B or C infection, active&#xD;
             tuberculosis, etc.);&#xD;
&#xD;
          2. Feasibility assessment and screening showed that the transfection of targeted&#xD;
             lymphocytes was less than 10% or the amplification was insufficient (&lt; 5 times) under&#xD;
             the co-stimulation of CD3/CD28.&#xD;
&#xD;
          3. The vital signs are abnormal, and those who cannot cooperate with the examination;&#xD;
&#xD;
          4. Those who have mental or psychological diseases can not cooperate with treatment and&#xD;
             efficacy evaluation;&#xD;
&#xD;
          5. Highly allergic constitution or severe allergic history, especially those who are&#xD;
             allergic to IL-2;&#xD;
&#xD;
          6. Subjects with systemic infection or severe local infection who need anti-infection&#xD;
             treatment;&#xD;
&#xD;
          7. Complicated with dysfunction of heart, lung, brain, liver, kidney and other important&#xD;
             organs;&#xD;
&#xD;
          8. Patients with other tumors;&#xD;
&#xD;
          9. Doctors believe that there are other reasons that can not be included in the&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junnian Zheng, M.D/Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hailong Li, M.D/Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Zhang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hailong Li, M.D/Ph.D</last_name>
    <phone>0086-17798835021</phone>
    <email>Justinlee719@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhang, Ph.D</last_name>
    <phone>0086-516-83262238</phone>
    <email>qingzhang@xzhmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailong Li, M.D/Ph.D</last_name>
      <phone>0086-17798835021</phone>
      <email>Justinlee719@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Linehan WM, Ricketts CJ. Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics. Nat Rev Urol. 2017 Feb;14(2):76-78. doi: 10.1038/nrurol.2016.260. Epub 2016 Dec 29. Review.</citation>
    <PMID>28031562</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther. 2013 Feb;13(1):65-70. Review.</citation>
    <PMID>23256743</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.</citation>
    <PMID>28541315</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu J, Tian K, Zhang H, Li L, Liu H, Liu J, Zhang Q, Zheng J. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. Expert Rev Anticancer Ther. 2017 Dec;17(12):1099-1106. doi: 10.1080/14737140.2017.1395285. Epub 2017 Oct 26. Review.</citation>
    <PMID>29048935</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology. 2019 May 11;8(5):e1049. doi: 10.1002/cti2.1049. eCollection 2019. Review.</citation>
    <PMID>31110702</PMID>
  </results_reference>
  <results_reference>
    <citation>Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.</citation>
    <PMID>23515080</PMID>
  </results_reference>
  <results_reference>
    <citation>Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology. 2014 Jan 1;3(1):e27680. Epub 2014 Feb 27.</citation>
    <PMID>24790793</PMID>
  </results_reference>
  <results_reference>
    <citation>Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>25317870</PMID>
  </results_reference>
  <results_reference>
    <citation>Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15.</citation>
    <PMID>28843072</PMID>
  </results_reference>
  <results_reference>
    <citation>Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.</citation>
    <PMID>25939063</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013 Apr;21(4):904-12. doi: 10.1038/mt.2013.17. Epub 2013 Feb 19.</citation>
    <PMID>23423337</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.</citation>
    <PMID>20889925</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carbonic anhydrase</keyword>
  <keyword>advanced renal cell carcinoma</keyword>
  <keyword>CAR-T</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>T cell</keyword>
  <keyword>CAIX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

